Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
NeoALTTO trial results

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 7042

Prof José Baselga – Massachusetts General Hospital Cancer Center, USA

A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumour response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the San Antonio Breast Cancer Symposium, December 2010. The study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumours and that lapatinib adds to trastuzumab. While further research is ongoing, the results indicate a potential improvement in the therapy of HER2-positive disease. The results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel. Prof Baselga also discusses adverse events.


Breast · Drug development · SABCS 2010

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation